189 related articles for article (PubMed ID: 28529091)
1. Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome.
Tofas P; Samarkos M; Piperaki ET; Kosmidis C; Triantafyllopoulou ID; Kotsopoulou M; Pantazatou A; Perlorentzou S; Poulli A; Vagia M; Daikos GL
Diagn Microbiol Infect Dis; 2017 Aug; 88(4):335-341. PubMed ID: 28529091
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy.
Tuon FF; Gortz LW; Rocha JL
Braz J Infect Dis; 2012; 16(4):351-6. PubMed ID: 22846123
[TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.
Endimiani A; Luzzaro F; Pini B; Amicosante G; Rossolini GM; Toniolo AQ
BMC Infect Dis; 2006 Mar; 6():52. PubMed ID: 16542460
[TBL] [Abstract][Full Text] [Related]
4. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours.
Marin M; Gudiol C; Ardanuy C; Garcia-Vidal C; Calvo M; Arnan M; Carratalà J
J Infect; 2014 Nov; 69(5):417-23. PubMed ID: 24960295
[TBL] [Abstract][Full Text] [Related]
5. Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study).
Bergas A; Albasanz-Puig A; Fernández-Cruz A; Machado M; Novo A; van Duin D; Garcia-Vidal C; Hakki M; Ruiz-Camps I; Del Pozo JL; Oltolini C; DeVoe C; Drgona L; Gasch O; Mikulska M; Martín-Dávila P; Peghin M; Vázquez L; Laporte-Amargós J; Durà-Miralles X; Pallarès N; González-Barca E; Álvarez-Uría A; Puerta-Alcalde P; Aguilar-Company J; Carmona-Torre F; Clerici TD; Doernberg SB; Petrikova L; Capilla S; Magnasco L; Fortún J; Castaldo N; Carratalà J; Gudiol C
Microbiol Spectr; 2022 Jun; 10(3):e0229221. PubMed ID: 35475683
[TBL] [Abstract][Full Text] [Related]
6. Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant
Zhen S; Zhao Y; Chen Z; Zhang T; Wang J; Jiang E; Zhang F; Mi Y; Zhu X; Han M; Xiao Z; Wang J; Feng S
Front Cell Infect Microbiol; 2023; 13():1156651. PubMed ID: 37415825
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of death with recurrent Pseudomonas aeruginosa bacteremia.
McCarthy KL; Paterson DL
Diagn Microbiol Infect Dis; 2017 Jun; 88(2):152-157. PubMed ID: 28366610
[TBL] [Abstract][Full Text] [Related]
8. Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study.
Vuotto F; Berthon C; Lemaitre N; Duhamel A; Balkaran S; Le Ray E; Micol JB; Faure K; Alfandari S
Am J Infect Control; 2013 Jun; 41(6):527-30. PubMed ID: 23219670
[TBL] [Abstract][Full Text] [Related]
9. A retrospective analysis of
Shi Q; Huang C; Xiao T; Wu Z; Xiao Y
Antimicrob Resist Infect Control; 2019; 8():68. PubMed ID: 31057792
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors and Outcomes of Antibiotic-resistant Pseudomonas aeruginosa Bloodstream Infection in Adult Patients With Acute Leukemia.
Zhao Y; Lin Q; Liu L; Ma R; Chen J; Shen Y; Zhu G; Jiang E; Mi Y; Han M; Wang J; Feng S
Clin Infect Dis; 2020 Dec; 71(Suppl 4):S386-S393. PubMed ID: 33367574
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009.
Zilberberg MD; Shorr AF
J Hosp Med; 2013 Oct; 8(10):559-63. PubMed ID: 24022878
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies.
Trecarichi EM; Tumbarello M; Caira M; Candoni A; Cattaneo C; Pastore D; Fanci R; Nosari A; Vianelli N; Busca A; Spadea A; Pagano L
Haematologica; 2011 Jan; 96(1):e1-3; author reply e4. PubMed ID: 21193424
[No Abstract] [Full Text] [Related]
13. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.
Gudiol C; Albasanz-Puig A; Laporte-Amargós J; Pallarès N; Mussetti A; Ruiz-Camps I; Puerta-Alcalde P; Abdala E; Oltolini C; Akova M; Montejo M; Mikulska M; Martín-Dávila P; Herrera F; Gasch O; Drgona L; Paz Morales H; Brunel AS; García E; Isler B; Kern WV; Morales I; Maestro-de la Calle G; Montero M; Kanj SS; Sipahi OR; Calik S; Márquez-Gómez I; Marin JI; Gomes MZR; Hemmatti P; Araos R; Peghin M; Del Pozo JL; Yáñez L; Tilley R; Manzur A; Novo A; Carratalà J;
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015035
[TBL] [Abstract][Full Text] [Related]
14. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection.
Suárez C; Peña C; Gavaldà L; Tubau F; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e73-8. PubMed ID: 20223693
[TBL] [Abstract][Full Text] [Related]
15. Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection.
Viasus D; Puerta-Alcalde P; Cardozo C; Suárez-Lledó M; Rodríguez-Núñez O; Morata L; Fehér C; Marco F; Chumbita M; Moreno-García E; Fernández-Avilés F; Gutiérrez-Garcia G; Martínez JA; Mensa J; Rovira M; Esteve J; Soriano A; Garcia-Vidal C
Clin Microbiol Infect; 2020 Mar; 26(3):345-350. PubMed ID: 31295551
[TBL] [Abstract][Full Text] [Related]
16. Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis.
Rojas A; Palacios-Baena ZR; López-Cortés LE; Rodríguez-Baño J
Clin Microbiol Infect; 2019 Aug; 25(8):964-970. PubMed ID: 30995530
[TBL] [Abstract][Full Text] [Related]
17. Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.
Buehrle DJ; Shields RK; Clarke LG; Potoski BA; Clancy CJ; Nguyen MH
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821456
[TBL] [Abstract][Full Text] [Related]
18. High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations.
Chumbita M; Puerta-Alcalde P; Yáñez L; Angeles Cuesta M; Chinea A; Español-Morales I; Fernandez-Abellán P; Gudiol C; González-Sierra P; Rojas R; Sánchez-Pina JM; Vadillo IS; Sánchez M; Varela R; Vázquez L; Guerreiro M; Monzo P; Lopera C; Aiello TF; Peyrony O; Soriano A; Garcia-Vidal C
Microbiol Spectr; 2023 Aug; 11(4):e0067423. PubMed ID: 37367629
[TBL] [Abstract][Full Text] [Related]
19. Systemic inflammatory response syndrome in adult patients with nosocomial bloodstream infection due to Pseudomonas aeruginosa.
Marra AR; Bar K; Bearman GM; Wenzel RP; Edmond MB
J Infect; 2006 Jul; 53(1):30-5. PubMed ID: 16253333
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
